ReviewChildren (Basel, Switzerland)2019
Quality of Life and Disease Impact of Atopic Dermatitis and Psoriasis on Children and Their Families.
Review in Children (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Atopic dermatitis in Ethiopia: a systematic review and meta-analysis.International health · 2026Pooled it
- Machine learning-derived asthma and allergy trajectories in children: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Maternal, Fetal, and Labour Outcomes of Dupilumab Use for Atopic Dermatitis During Pregnancy: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.Acta dermato-venereologica · 2024Trial
- Trial
- Assessment of Common Food Allergens in Infants With Atopic Dermatitis in Kashan From 2005 to 2021.Immunity, inflammation and disease · 2026Article
- The Association of Longitudinal Atopic Dermatitis Phenotypes and Attention-Deficit/Hyperactivity Disorder in Childhood.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- Article
- Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System.American journal of clinical dermatology · 2026Observational
- Digital psychotherapeutic interventions to reduce dermatological symptom burden: Development and testing of MindMySkin.JAAD international · 2026Article
- Cost-Effectiveness Analysis of Abrocitinib Compared with Dupilumab for Adolescents With Severe Atopic Dermatitis in Spain.PharmacoEconomics - open · 2026Article
- Efficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study.Annals of medicine · 2025Article
- Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis.Dermatology and therapy · 2025Review
- The ChinaSTAD Chinese Registry in Patients with Moderate-To-Severe Atopic Dermatitis Not Controlled by Topical Therapy: Baseline Characteristics, Disease Burden and Treatment.Dermatology and therapy · 2025Article
- Article
- Brianolide fromBiomolecules · 2025Article
- Phenotypes of Atopic Dermatitis and Development of Allergic Diseases.JAMA network open · 2025Observational
- A 'normal' life: a qualitative study exploring parents' experiences of everyday life with a child diagnosed with atopic dermatitis and atopic comorbidities.Scandinavian journal of primary health care · 2025Article
- Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study.Dermatology and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) and psoriasis are common chronic skin diseases affecting children. These disorders negatively impact the quality of life (QoL) of patients in health-related aspects such as physical, psychosocial, and mental functioning. This health impact is more accurately represented when accounting for the numerous comorbidities associated with each disorder, and the impact the disorders have on patients' families. A number of QoL tools have been developed and can be routinely implemented in the evaluation of QoL in pediatric patients and their caregivers. Ways to improve QoL include a multidisciplinary approach to care, education, and psychological support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.